Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 15/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8481079 | 0.88 | TACR1 (0.64) | TACR1CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL8479202 | 0.86 | TACR1 (0.63) | TACR1CA1CA2CA4CA9 | |
| SCHEMBL7827040 | 0.85 | TACR1 (0.71) | TACR1 | |
| SCHEMBL7828684 | 0.85 | TACR1 (0.50) | TACR1CA1CA2CA4CA9 | |
| SCHEMBL7828222 | 0.85 | TACR1 (0.71) | TACR1 | |
| SCHEMBL5520838 | 0.85 | TACR1 (0.61) | TACR1CA1CA2CA4CA9 | |
| SCHEMBL5366437 | 0.85 | TACR1 (0.61) | TACR1CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL7826462 | 0.84 | TACR1 (0.70) | TACR1 | |
| SCHEMBL7826647 | 0.84 | TACR1 (0.51) | TACR1CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL7830176 | 0.84 | TACR1 (0.51) | TACR1CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| US-6087357-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | PKD2, SSTR5, TAC3 | TACR1 5/4885CA1 2077/4885CA2 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.